Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**68Ga-XT771** is a novel radiopharmaceutical imaging agent labeled with the radionuclide gallium-68 (^68Ga), developed for use in positron emission tomography (PET) imaging. It specifically targets **carbonic anhydrase IX (CAIX)** and **carbonic anhydrase XII (CAXII)** proteins, which are highly expressed in certain tumors, notably **glioblastoma** and **clear cell renal cell carcinoma**. By binding to these proteins, 68Ga-XT771 enables the visualization of tumor cells in vivo using PET/CT imaging. The agent is currently being evaluated in early-phase clinical trials for its diagnostic utility and safety in oncologic imaging[1][2][3][5][6][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-XT771.